Orhun H. Kantarci, M.D.

The purposes of this study are to explore the association between female sex, reproductive history and clinical phenotypic variability in multiple sclerosis (MS), to explore the association between female sex, reproductive history and radiologic phenotypic variability in MS, and to explore the association between female sex, genetic and environmental interactions in MS.

The purpose of this study is:

1. To develop an Emoji Based Neurological Impairment Status scale to assess the patient neurological status
2. To determine the level of impairment in cognitive functions, mood, fatigue and ambulation by using emoji
3. To validate the Emoji Based Neurological Impairment Status by comparing with neurological examination and current tests which were validated for cognition, mood, fatigue and ambulation

The purpose of this study is to determine whether an EHT approach to DMT, defined as use of one of five monoclonal antibodies (alemtuzumab, natalizumab, rituximab, ocrelizumab, ofatumumab) as first-line therapy, is more effective than an escalation of treatment approach in reducing normalized whole brain volume loss measured using MRI in PwRRMS from Baseline to Month 36.

Multi-center pragmatic comparative effectiveness randomized clinical trial with additional-parallel observational cohort.
The DELIVER-MS study seeks to answer the important question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding the decision for medication approval by third parties

The purpose of this study is to answer the important question: Does early treatment with highly effective DMT (Disease Modifying Therapy) improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians.  

The purpose of this investigation is to systematically study the efficacy of Tecfidera in those individuals who possess incidental white matter anomalies within the brain following a MRI study that is performed for a reason other than for the evaluation of MS (multiple sclerosis).